Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

FDA OKs Phase 2 trials for Dyve gout treatment

By   /   Tuesday, December 10th, 2019  /   Comments Off on FDA OKs Phase 2 trials for Dyve gout treatment

    Print       Email
Thousand Oaks dermatology biotech firm Dyve Biosciences got the nod from regulators to send its topical pain and gout treatment through Phase 2 trials. The privately held firm announced Dec. 9 that additional clinical trials of its product, DYV-700, had been approved by the U.S. Food and Drug Administration, and are planned to begin in…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email